# non-muscle invasive bladder cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/non-muscle-invasive-bladder-cancer

> 2 upcoming FDA catalysts in non-muscle invasive bladder cancer: ndv01 intravesical controlled release formulation of gemcitabine and docetaxel (RLMD) on November 2027 (primary completion); ndv01 intravesical controlled release formulation of gemcitabine and docetaxel (RLMD) on Nov 2027 to Feb 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q4 2024 | [TARA-002 interim data readout](https://sec-api.dev/pdufa/tara-002) | TARA | non-muscle invasive bladder cancer | scheduled | "On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390024096243/ea021925801ex99-1_protara.htm)) |
| April 28, 2025 | [NDV-01 interim data readout](https://sec-api.dev/pdufa/ndv-01) | RLMD | non-muscle invasive bladder cancer | completed, positive | "On April 28, 2025, the Company announced positive initial data from the Phase 2 study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1553643/000121390025073073/ea0248747-10q_relmada.htm)) |
| June 16, 2025 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Muscle- Invasive Bladder Cancer | completed | "NCT05943106 (BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-16 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05943106)) |
| November 2027 | [Ndv01 intravesical controlled release formulation of gemcitabine and docetaxel primary completion](https://sec-api.dev/pdufa/ndv01-intravesical-controlled-release-formulation-of-gemcitabine-and-docetaxel) | RLMD | Non Muscle Invasive Bladder Cancer | scheduled | "NCT06663137 (A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Relmada Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06663137)) |
| Nov 2027 to Feb 2028 | [Ndv01 intravesical controlled release formulation of gemcitabine and docetaxel topline data readout](https://sec-api.dev/pdufa/ndv01-intravesical-controlled-release-formulation-of-gemcitabine-and-docetaxel) | RLMD | Non Muscle Invasive Bladder Cancer | scheduled | "NCT06663137 (A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Relmada Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06663137)) |

## Drugs

- [TARA-002](https://sec-api.dev/pdufa/tara-002) (TARA)
- [NDV-01](https://sec-api.dev/pdufa/ndv-01) (RLMD)
- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)
- [Ndv01 intravesical controlled release formulation of gemcitabine and docetaxel](https://sec-api.dev/pdufa/ndv01-intravesical-controlled-release-formulation-of-gemcitabine-and-docetaxel) (RLMD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/non-muscle-invasive-bladder-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "non-muscle invasive bladder cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/non-muscle-invasive-bladder-cancer

```bibtex
@misc{secapidev_indications_non_muscle_invasive_bladder_cancer_20261116,
  title        = {non-muscle invasive bladder cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/non-muscle-invasive-bladder-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_non_muscle_invasive_bladder_cancer_20261116","title":"non-muscle invasive bladder cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/non-muscle-invasive-bladder-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
